Duncan Williams Maintains Cadence Pharmaceuticals Strong Buy, $14 PT

Duncan Williams maintained its Cadence Pharmaceuticals CADX Strong Buy rating and $14 price target in a research report published today. In the report, Duncan Williams states, "We have not yet seen any weakness in the vial sales and formulary approvals have exceeded our expectations." Shares of Cadence Pharmaceuticals were trading at $8.94 at the time of posting, down 1.32% from Friday's market close.